Patients with pulmonary arterial hypertension (PAH) were more likely to die or be hospitalized if they contracted COVID-19 but were less likely to die from COVID-19 if they were vaccinated against SARS-CoV-2.
Patients with a diagnosis of pulmonary arterial hypertension (PAH) who were vaccinated against COVID-19 were less likely to contract the virus compared with unvaccinated people, according to a study published in Polish Archives of Internal Medicine. In addition, patients with a diagnosis of PAH were more likely to be hospitalized or die from COVID-19 if they contracted the virus.
Patients with underlying health conditions, especially underlying health conditions that involved the respiratory system, have a higher risk of suffering from severe COVID-19. This observational, multicenter, cohort study was conducted to evaluate the relationship between patients with a diagnosis of PAH and the outcomes of COVID-19.
The was conducted from March 11, 2020, to March 11, 2022. Patients who were admitted to 3 pulmonary hypertension (PH) centers in Poland during this period were included (N = 364); all had . All patients had regular follow-ups and were in contact with the centers every 2 to 3 months during this time. None of the centers were focused on treating patients with COVID-19.
Patients were included if they had diagnosed PAH, were confirmed to have acute COVID-19 infection, and were 18 years or older. All clinical information was collected from their medical records. Patients were considered fully vaccinated at least 2 weeks after receiving the second dose of a COVID-19 vaccine or 2 weeks after receiving the single dose of the Johnson & Johnson vaccine.
Most patients in this study were femalepatients, and the median (IQR) age was 61 (42-73) years. The median (IQR) length of follow-up was 730 (601-730) days. Patients with PAH made up 66% of the participants, with the remaining 34% classified as having chronic thromboembolic pulmonary hypertension (CTEPH).
The researchers found that patients who were unvaccinated contracted COVID-19 more frequently than patients who were vaccinated (46% vs 9%). The risk of COVID-19 was lowered in patients with PAH and CTEPH who were vaccinated.
Twnety-three percent of the patients included contracted COVID-19 during the 2 years of this study, 38% contracted COVID-19 prior to the vaccination program, and 62% became ill when vaccinations were available and 26% when the Omicron variant appeared.
Prior to the vaccination program, 41% of patients who had COVID-19 needed to be hospitalized and 22% required intensive care unit (ICU) treatment. All patients who were moved to the ICU eventually died, and the overall mortality rate was 54% in patients with PAH or CTEPH. No patient required ICU admission after COVID-19 vaccinations, but 24.5% did need to be hospitalized.
A total of 33% of patients needed to be hospitalized in the unvaccinated group after vaccines became available, with 11% requiring ICU admission and later dying. No patients with a diagnosis of PAH or CTEPH who was vaccinated died during the postvaccination period.
There were some limitations to this study. The group studied was relatively small and was evaluated in a retrospective nature, and asymptomatic patients could have been omitted from this study due to only testing patients with clear symptoms. In addition, a study survival analysis may have been better than the logistic regression model used in this study.
The researchers concluded that patients with a diagnosis of PAH or CTEPH were well protected against COVID-19 if they were vaccinated, as unvaccinated patients with PH had a higher mortality risk and hospitalization rate compared with the general population.
Reference
Wieteska-Milek M, Kusmierczyk-Droszcz B, Ryczek R, et al. Outcomes of COVID-19 in patients vaccinated and unvaccinated against SARS-CoV-2 and suffering from pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Pol Arch Intern Med. Published online January 5, 2023. doi:10.20452/pamw.16406
Reducing Time Sitting Can Help Lower BP in Older Adults, Randomized Trial Finds
April 20th 2024The randomized trial found that reducing sitting time over a 6-month period was association with reduced systolic blood pressure (BP) among a group of older patients with obesity and high rates of hypertension.
Read More
Targeting MACC1 Offers Promising Therapeutic Strategy for PAH
April 10th 2024Positive responses seen following experiments involving metastasis-associated in colon cancer 1 (MACC1) indicate that the biomarker can be used to better diagnose and treat patients with pulmonary arterial hypertension (PAH).
Read More
Pandemic Care Gaps Associated With Loss of Hypertension Control, Study Finds
April 3rd 2024Surprisingly, the investigators found people with uncontrolled hypertension before the pandemic actually had a slightly higher chance of getting their blood pressure under control during the crisis.
Read More